Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.33 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL695227 | 0.80 | SLC6A7 (0.41) | SLC6A7HDAC1HDAC2HDAC3CHEK1 | |
| SCHEMBL72613 | 0.78 | AR (0.43) | SLC6A7GRIN2BGRIN1HSD17B1HSD17B2 | |
| SCHEMBL2874184 | 0.77 | SLC6A7 (0.33) | SLC6A7HDAC1HDAC2HDAC3CHEK1 | |
| SCHEMBL4200384 | 0.75 | CNR1 (0.41) | SLC6A7HDAC1HDAC2HDAC3CHEK1 | |
| SCHEMBL13183603 | 0.75 | HSD17B1 (0.44) | SLC6A7HSD17B1HSD17B2CYP3A4CYP2D6 | |
| SCHEMBL28268808 | 0.75 | HSD17B1 (0.55) | SLC6A7HDAC1HDAC2HDAC3HSD17B1 | |
| SCHEMBL6219607 | 0.75 | HSD17B1 (0.32) | HSD17B1HSD17B2CYP3A4 | |
| SCHEMBL5615209 | 0.75 | HSD17B1 (0.30) | HSD17B1HSD17B2 | |
| SCHEMBL9773308 | 0.74 | DAO (0.44) | SLC6A7HDAC1HDAC2HDAC3CHEK1 | |
| SCHEMBL28147641 | 0.72 | HDAC1 (0.40) | SLC6A7HDAC1HDAC2HDAC3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101193635-A | Multicyclic compounds and methods of their use | LEXICON GENETICS INC (US) | 2008-06-04 | — | — | CN | claimed |
| US-7906556-B2 | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-7858642-B2 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080166332-A1 | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1937638-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7385085-B2 | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| CN-101193635-A | Multicyclic compounds and methods of their use | LEXICON GENETICS INC (US) | 2008-06-04 | — | — | CN | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2005-10-06 | — | — | US | disclosed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087215-A1 | SUBSTITUTED UREA AND CARBAMATE, PHENACYL-2-HYDROXY-3-DIAMINOALKANE, AND BENZAMIDE-2-HYDROXY-3-DIAMINOALKANE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005058808-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | MMP13, MMP11, MMP3 | SLC6A7 676/4885HDAC1 214/4885HDAC2 497/4885 |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | SLC6A7 232/4885HDAC1 2603/4885HDAC2 2848/4885 |
| US-20090042961-A1 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ASPH, DNPEP, APP | SLC6A7 685/4885HDAC1 2952/4885HDAC2 3012/4885 |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | MMP13, MMP11, MMP1 | SLC6A7 739/4885HDAC1 210/4885HDAC2 438/4885 |
| US-20080166332-A1 | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | AMY1A, AMY2A, DNPEP | SLC6A7 544/4885HDAC1 2931/4885HDAC2 3694/4885 |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | SLC6A7 764/4885HDAC1 3029/4885HDAC2 3272/4885 |
| US-20090270367-A1 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | DNPEP, MME, ANPEP | SLC6A7 232/4885HDAC1 2603/4885HDAC2 2848/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | SLC6A7 232/4885HDAC1 2603/4885HDAC2 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.